Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia

被引：5

作者：

Bacher, U ^{[1
]}

Kern, W ^{[1
]}

Schnittger, S ^{[1
]}

Hiddemann, W ^{[1
]}

Schoch, C ^{[1
]}

Haferlach, T ^{[1
]}

机构：

[1] Univ Munich, Lab Leukemia Diagnost, Klinikum Grosshadern, Dept Internal Med 3, D-81377 Munich, Germany

来源：

LEUKEMIA & LYMPHOMA | 2005年 / 46卷 / 03期

关键词：

CML; cytomorphology; cytogenetics; clonal evolution;

D O I：

10.1080/10428190400013068

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Staging of chronic myeloid leukemia (CML) phases is based on cytomorphological criteria that vary considerably between different staging systems. Thus, staging of CML is heterogeneous and causes problems with respect to the comparison of therapeutical strategies and clinical outcome. We evaluated 59 patients with CML in different stages of the disease. In order to de. ne which cytomorphological parameters correlate with cytogenetics we investigated cytomorphology and cytogenetics in parallel in all cases. As a result, bone marrow blast count demonstrated a highly significant correlation with the respective cytogenetic results of the patients and was clearly linked to the frequency and complexity of clonal evolution. We therefore propose to focus staging systems of CML on the correlation of the percentage of bone marrow blasts and the cytogenetic results.

引用

页码：357 / 366

页数：10

共 26 条

[21] PATTERNS OF CLONAL EVOLUTION IN TRANSFORMED CHRONIC MYELOGENOUS LEUKEMIA [J].

RUFF, P ;

SARAGAS, E ;

POULOS, M ;

WEAVING, A .

CANCER GENETICS AND CYTOGENETICS, 1995, 81 (02) :182-184

[22] Bone marrow transplantation for chronic myeloid leukaemia: The effects of differing criteria for defining chronic phase on probabilities of survival and relapse [J].

Savage, DG ;

Szydlo, RM ;

Chase, A ;

Apperley, JF ;

Goldman, JM .

BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (01) :30-35

[23] Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate [J].

Schoch, C ;

Haferlach, T ;

Kern, W ;

Schnittger, S ;

Berger, U ;

Hehlmann, R ;

Hiddemann, W ;

Hochhaus, A .

LEUKEMIA, 2003, 17 (02) :461-463

[24] Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases [J].

Schoch, C ;

Schnittger, S ;

Bursch, S ;

Gerstner, D ;

Hochhaus, A ;

Berger, U ;

Hehlmann, R ;

Hiddemann, W ;

Haferlach, T .

LEUKEMIA, 2002, 16 (01) :53-59

[25] Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study [J].

Talpaz, M ;

Silver, RT ;

Druker, BJ ;

Goldman, JM ;

Gambacorti-Passerini, C ;

Guilhot, F ;

Schiffer, CA ;

Fischer, T ;

Deininger, MWN ;

Lennard, AL ;

Hochhaus, A ;

Ottmann, OG ;

Gratwohl, A ;

Baccarani, M ;

Stone, R ;

Tura, S ;

Mahon, FX ;

Fernandes-Reese, S ;

Gathmann, I ;

Capdeville, R ;

Kantarjian, HM ;

Sawyers, CL .

BLOOD, 2002, 99 (06) :1928-1937

[26] Bone marrow features and clinical findings in chronic myeloid leukemia - A comparative, multicenter, immunohistological and morphometric study on 614 patients [J].

Thiele, J ;

Kvasnicka, HM ;

Schmitt-Graeff, A ;

Zirbes, TK ;

Birnbaum, F ;

Kressmann, C ;

Melguizo-Grahmann, M ;

Frackenpohl, H ;

Sprungmann, C ;

Leder, LD ;

Diehl, V ;

Zankovich, R ;

Schaefer, HE ;

Niederle, N ;

Fischer, R .

LEUKEMIA & LYMPHOMA, 2000, 36 (3-4) :295-+

← 1 2 3 →